Arcturus Therapeutics Holdings Inc. Common Stock (ARCT)
Stock · NASDAQ · Health Care
$10.35as of 10/16/2026
Price chart
Active signals
ARCT Signal Track Record
How signals performed across all stocks →What ARCT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +3.7% | 57% | September 17, 2026 |
| Bollinger Band Breakout | 28 | -1.8% | 50% | August 7, 2026 |
| Bollinger Band BreakdownActive now | 17 | +5.3% | 65% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +1.4% | 56% | July 23, 2025 |
| Any 20-session window (baseline) | -1.2% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ARCT
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; an…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 106
- Website
- arcturusrx.com/
Fundamentals
- 1-day range
- $10.25$11.31
- Market cap
- $172.81M
- P/E (trailing)
- —
- P/E (forward)
- -2.79
- EPS (trailing)
- $-3.31
- Dividend yield
- —
- Beta
- 2.60
- Avg. volume
- 943.6K
- Dividend pay date
- November 16, 2017
How Arcturus Therapeutics Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Arcturus Therapeutics Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ARCTArcturus Therapeutics Holdings Inc. Common Stock$10.34▼ 8.25%Market cap $172.81MP/E —$5.5$24.17
- KRROKorro Bio Inc. Common Stock$8.49▼ 8.81%Market cap $174.80MP/E —$5.2$55.89
- OKUROnKure Therapeutics Inc. Class A Common Stock$2.1▼ 1.41%Market cap $168.06MP/E —$2.13$5.38
- ORMPOramed Pharmaceuticals Inc. Common Stock$4.07▼ 2.63%Market cap $178.87MP/E 0.98$2.09$5.47
- PEPGPepGen Inc. Common Stock$2.6▲ 2.77%Market cap $166.70MP/E —$1.31$7.8
- INDPIndaptus Therapeutics Inc. Common Stock$2.63▼ 7.72%Market cap $166.55MP/E —$0.92$5.96
- DERMJourney Medical Corporation Common Stock$4.97▼ 3.12%Market cap $179.80MP/E —$4.31$9.56
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings Inc. Common Stock | $172.81M | — | $10.34 | ▼ 8.25% | $5.5$24.17 |
| KRRO Korro Bio Inc. Common Stock | $174.80M | — | $8.49 | ▼ 8.81% | $5.2$55.89 |
| OKUR OnKure Therapeutics Inc. Class A Common Stock | $168.06M | — | $2.1 | ▼ 1.41% | $2.13$5.38 |
| ORMP Oramed Pharmaceuticals Inc. Common Stock | $178.87M | 0.98 | $4.07 | ▼ 2.63% | $2.09$5.47 |
| PEPG PepGen Inc. Common Stock | $166.70M | — | $2.6 | ▲ 2.77% | $1.31$7.8 |
| INDP Indaptus Therapeutics Inc. Common Stock | $166.55M | — | $2.63 | ▼ 7.72% | $0.92$5.96 |
| DERM Journey Medical Corporation Common Stock | $179.80M | — | $4.97 | ▼ 3.12% | $4.31$9.56 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Callbenzinga · 10/14/2026
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On FridayBenzinga · 10/9/2026
- CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For FridayBenzinga · 10/9/2026
- Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19Benzinga · 10/9/2026
- 4 RNA Therapeutics Stocks Leading the Next Wave of InnovationYahoo · 9/28/2026
- Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy PlatformYahoo · 9/25/2026
- Why Is Arcturus Therapeutics Stock Gaining Thursday?Benzinga · 9/24/2026
- Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst callsYahoo · 9/24/2026
- Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20Benzinga · 9/24/2026
Insider Activity
Insider Actions →- John Markels · June 5, 2026 · Grant15.0K
- Jing L. Marantz · June 5, 2026 · Grant15.0K
- Slaoui Moncef · June 5, 2026 · Grant15.0K
- Magda Marquet · June 5, 2026 · Grant15.0K
- Edward W. Holmes · June 5, 2026 · Grant15.0K
- James F. Barlow · June 5, 2026 · Grant15.0K
- Peter C. Farrell · June 5, 2026 · Grant15.0K
- Dennis Mulroy · May 1, 2026 · Grant100.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 23.34M
- Total value held
- $176.35M
- Institutional holders
- 122
- Unknown3.30M
- Unknown2.77M
- Unknown2.61M
- Unknown2.29M
- Unknown2.29M
- Unknown1.11M
- Unknown1.08M
- Unknown660.9K
- Unknown543.9K
- Unknown478.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Arcturus Shares Rise on Phase II Data and Analyst Upgrades
Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.
Arcturus Shares Rise on Phase II Data and Analyst Upgrades. Arcturus Therapeutics reported positive Phase II data for ARCT-810 and introduced a new over-the-counter therapy platform. These updates coincided with Citigroup upgrading the stock to Buy and raising its price target to $20. The company also discussed progress in its mRNA liver therapeutics platform, contributing to the recent share price movement.